About Dov Goldstein
Dov Goldstein is a director at Gain Therapeutics.
Form D filings name Dov Goldstein as an executive officer at BioAge Labs.
Dov Goldstein reports to the SEC as a director, officer or major shareholder of 9 public companies, including BioAge Labs (BIOA), Coya Therapeutics (COYA) and NeuBase Therapeutics (NBSE).
Dov Goldstein first appears on SEC filings in 2012.
Experience
This experience comes from SEC filings. The years are when the filings name Dov Goldstein in the role, so the role may have started earlier or lasted longer.
GI
Gain Therapeutics, Inc.
Director
2021 – 2026 · Public company (GANX)
CI
Coya Therapeutics, Inc.
Director
2022 – 2026 · Public company (COYA)
NI
NeuBase Therapeutics, Inc.
Director
2019 – 2022 · Public company (NBSE)
AI
Adma Biologics, Inc.
Director and 10% owner
2012 – 2020 · Public company (ADMA)
EI
Esperion Therapeutics, Inc.
Director
2013 – 2018 · Public company (ESPR)
MN
Melinta Therapeutics, Inc. /new/
Director
2012 – 2017 · Public company (MLNT)
LI
Loxo Oncology, Inc.
CFO and Treasurer, director
2014 – 2015 · Public company (LOXO)
DI
Durata Therapeutics, Inc.
Director and 10% owner
2012 · Public company (DRTX)
Key Colleagues at Startups
The people Dov Goldstein works with at each company, as listed on that company's latest Form D.
BioAge Labs, Inc. · Form D, Feb 13, 2024
EM
Eric Morgen
Director
JC
Jason Coloma
Director
KF
Kristen Fortney
CEO and director
PE
Patrick Enright
Director
VP
Vijay Pande
Director
RH
Rehka Hemrajani
Director
JH
James Healy
Director